Skip to main content
. 2022 Feb 8;23(3):1917. doi: 10.3390/ijms23031917

Table 2.

Additional characteristics of IDA controls.

IDA Controls (n = 39)
Characteristics N Median or Count (%) IQR
ALT, U/L 21 18.0 16.0–25.0
eGFR (CKD-EPI), mL/min/1.73 m2 a 33 89 65–≥90
BMI, kg/m2 39 28 24–34

  • Normal weight (18.5–24.9)

 11 (28)

  • Overweight (25–29.9)

 9 (23)

  • Obese (≥30)

 17 (44)

  • Unknown

 2 (5)
Assessment of underlying disorder of IDA 39 N/A

  • Gastrointestinal bleeding

 12 (31)

  • Gynecological bleeding

 5 (13)

  • Malabsorption

 4 (10)

  • Unexplained IDA

 18 (46)
Assessment of medication use 39 N/A

  • Anticoagulants

 6 (15)

  • Antithrombotic agents

 12 (31)

  • NSAIDs

 1 (3)

  • Proton pump inhibitors

 14 (36)

  • Corticosteroids

 1 (3)
Assessment of response to iron therapy in unexplained IDA b 18 N/A

  • Hb increase < 2.0 g/dL after oral iron

 1 (6)

  • Hb increase < 2.0 g/dL after IV iron

 1 (6)

  • Hb increase ≥ 2.0 g/dL after oral iron

 4 (22)

  • Hb increase ≥ 2.0 g/dL after IV iron

 9 (50)

  • No iron supplementation

 3 (17)

a eGFR was ≥90 mL/min/1.73 m2 in 49% (n = 16), 60–89 mL/min/1.73 m2 in 30% (n = 10), 45–59 mL/min/1.73 m2 in 18% (n = 6) and 30–44 mL/min/1.73 m2 in 3% (n = 1). b Response to iron therapy 3 weeks after initiation of iron supplementation. IDA, iron deficiency anemia; IQR, interquartile range; N/A, not applicable; ALT, alanine aminotransferase; eGFR, estimated Glomerular Filtration Rate; BMI, body mass index; Hb, hemoglobin, NSAIDs, non-steroidal anti-inflammatory drugs; IV, intravenous.